ICU Medical, Inc. (ICUI)
NASDAQ: ICUI · Real-Time Price · USD
144.34
+6.04 (4.37%)
At close: May 12, 2025, 4:00 PM
147.14
+2.80 (1.94%)
After-hours: May 12, 2025, 4:12 PM EDT
ICU Medical Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ICU Medical stock have an average target of 196.75, with a low estimate of 187 and a high estimate of 209. The average target predicts an increase of 36.31% from the current stock price of 144.34.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ICU Medical stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 2 |
| Buy | 2 | 2 | 2 | 2 | 3 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Strong Buy Maintains $197 → $187 | Strong Buy | Maintains | $197 → $187 | +29.56% | May 9, 2025 |
| Keybanc | Keybanc | Buy Maintains $209 → $191 | Buy | Maintains | $209 → $191 | +32.33% | Apr 21, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Apr 8, 2025 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $200 | Hold → Strong Buy | Upgrades | $200 | +38.56% | Dec 11, 2024 |
| Keybanc | Keybanc | Buy Maintains $198 → $209 | Buy | Maintains | $198 → $209 | +44.80% | Nov 13, 2024 |
Financial Forecast
Revenue This Year
2.40B
from 2.38B
Increased by 0.84%
Revenue Next Year
2.47B
from 2.40B
Increased by 2.91%
EPS This Year
6.78
from -4.83
EPS Next Year
8.34
from 6.78
Increased by 23.07%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.5B | 2.6B | 2.7B | ||
| Avg | 2.4B | 2.5B | 2.6B | ||
| Low | 2.1B | 2.1B | 2.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.2% | 9.6% | 9.7% | ||
| Avg | 0.8% | 2.9% | 5.6% | ||
| Low | -11.6% | -12.1% | -0.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.39 | 9.06 | 11.15 | ||
| Avg | 6.78 | 8.34 | 10.08 | ||
| Low | 5.29 | 6.37 | 9.32 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 33.7% | 33.7% | ||
| Avg | - | 23.1% | 20.9% | ||
| Low | - | -6.0% | 11.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.